Pulmonary Hypertension in Patients with Chronic Kidney Disease on Dialysis and Without Dialysis: Results of the PEPPER-study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Apr 25

PMID 22530005

Citations 54

Authors

Stefan Pabst

Christoph Hammerstingl

Felix Hundt

Thomas Gerhardt

Christian Grohe

Georg Nickenig

Rainer Woitas

Dirk Skowasch

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension (PH) is common in patients with dialysis-dependent chronic kidney disease and is an independent predictor of mortality. However, specific hemodynamics of the pulmonary circulation, changes induced by hemodialysis and characterization into pre- or postcapillary PH have not been evaluated in patients with chronic kidney disease. We assessed consecutive patients with end-stage chronic kidney disease in WHO FC ≥ II with dyspnea unexplained by other causes on hemodialysis (group 1, n = 31) or without dialysis (group 2, n = 31) using right heart catheterization (RHC). In group 1, RHC was performed before and after dialysis. In end-stage chronic kidney disease, prevalence of precapillary PH was 13% (4/31), and postcapillary PH was discovered in 65% (20/31). All four cases of precapillary PH were unmasked after dialysis. In group 2, two cases of precapillary PH were detected (6%), and postcapillary PH was diagnosed in 22 cases (71%). This is the first study examining a large cohort of patients with chronic kidney disease invasively by RHC for the prevalence of PH. The prevalence of precapillary PH was 13% in patients with end-stage kidney disease. That suggests careful screening for precapillary PH in this selected patient population. RHC should be performed after hemodialysis.

Citing Articles

Contributing Factors of Pulmonary Hypertension in Hemodialysis Patients.

Behzadnia N, Esmaeilinejad K, Rashid-Farokhi F, Pourdowlat G Tanaffos. 2024; 22(4):375-381.

PMID: 39176142 PMC: 11338510.

Predictors, prevalence and prognostic role of pulmonary hypertension in patients with chronic kidney disease: a systematic review and meta-analysis.

Lin C, Ge Q, Wang L, Zeng P, Huang M, Li D Ren Fail. 2024; 46(2):2368082.

PMID: 38938193 PMC: 11216249. DOI: 10.1080/0886022X.2024.2368082.

Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes.

Zeder K, Siew E, Kovacs G, Brittain E, Maron B Nat Rev Nephrol. 2024; 20(11):742-754.

PMID: 38890546 DOI: 10.1038/s41581-024-00857-7.

Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.

Complexities and outcomes of pulmonary hypertension in kidney transplant patients: a comprehensive review.

Lentine K, Levine D, Runo J, Caliskan Y, Costa S, Lam N Turkish J Nephrol. 2024; 33(1):8-26.

PMID: 38213512 PMC: 10783548.

References

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

Tomic M, Galesic K, Markota I . Endothelin-1 and nitric oxide in patients on chronic hemodialysis. Ren Fail. 2008; 30(9):836-42. DOI: 10.1080/08860220802356218. View

Arese M, Strasly M, Ruva C, Costamagna C, Ghigo D, Macallister R . Regulation of nitric oxide synthesis in uraemia. Nephrol Dial Transplant. 1995; 10(8):1386-97. View

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC. View

El-Shafey E, El-Nagar G, Selim M, El-Sorogy H, Sabry A . Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis?. Clin Exp Nephrol. 2008; 12(5):370-375. DOI: 10.1007/s10157-008-0065-2. View

Yigla M, Fruchter O, Aharonson D, Yanay N, Reisner S, Lewin M . Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int. 2009; 75(9):969-75. DOI: 10.1038/ki.2009.10. View

Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O . Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007; 74(5):503-10. DOI: 10.1159/000102953. View

Stefanidis I, Wurth P, Mertens P, Ikonomov V, Philippidis G, Golphinopoulos S . Plasma endothelin-1 in hemodialysis treatment - the influence of hypertension. J Cardiovasc Pharmacol. 2005; 44 Suppl 1:S43-8. DOI: 10.1097/01.fjc.0000166215.50415.36. View

Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34(6):1219-63. DOI: 10.1183/09031936.00139009. View

10.

Unal A, Tasdemir K, Oymak S, Duran M, Kocyigit I, Oguz F . The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. Hemodial Int. 2010; 14(4):398-402. DOI: 10.1111/j.1542-4758.2010.00478.x. View

11.

Ramasubbu K, Deswal A, Herdejurgen C, Aguilar D, Frost A . A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med. 2010; 3:279-86. PMC: 2962323. DOI: 10.2147/IJGM.S12946. View

12.

Aznar-Salatti J, Escolar G, Cases A, Gomez-Ortiz G, Anton P, Castillo R . Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix. Nephrol Dial Transplant. 1995; 10(12):2199-204. DOI: 10.1093/ndt/10.12.2199. View

13.

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

14.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

15.

Thambyrajah J, Landray M, McGlynn F, Jones H, Wheeler D, Townend J . Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 2000; 83(2):205-9. PMC: 1729306. DOI: 10.1136/heart.83.2.205. View

16.

Simonneau G, Robbins I, Beghetti M, Channick R, Delcroix M, Denton C . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43-S54. DOI: 10.1016/j.jacc.2009.04.012. View

17.

Bozbas S, Akcay S, Altin C, Bozbas H, Karacaglar E, Kanyilmaz S . Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc. 2009; 41(7):2753-6. DOI: 10.1016/j.transproceed.2009.07.049. View

18.

Liefeldt L, van Giersbergen P, Dingemanse J, Rudolph B, Walde T, Budde K . Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis. 2004; 43(5):923-6. DOI: 10.1053/j.ajkd.2003.12.054. View

19.

Nakhoul F, Yigla M, Gilman R, Reisner S, Abassi Z . The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant. 2005; 20(8):1686-92. DOI: 10.1093/ndt/gfh840. View

20.

Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z . Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003; 123(5):1577-82. DOI: 10.1378/chest.123.5.1577. View